# A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA

> **NCT03764618** · PHASE3 · COMPLETED · sponsor: **Rigel Pharmaceuticals** · enrollment: 90 (actual)

## Conditions studied

- Warm Antibody Autoimmune Hemolytic Anemia

## Interventions

- **DRUG:** Fostamatinib disodium
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03764618
- **Lead sponsor:** Rigel Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-24
- **Primary completion:** 2022-04-11
- **Final completion:** 2022-04-11
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2023-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03764618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03764618, "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03764618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*